PD-1 Identifies Patient-Specific CD8-Positive Tumor-Infiltrating Lymphocytes in Melanoma


Get Permission

Adoptive transfer of tumor-infiltrating lymphocytes can mediate regression of metastatic melanoma. However, there are no effective markers to identify and select patient-specific repertoires of tumor-reactive and mutation-specific CD8-positive lymphocytes, limiting the ability to develop strategies to increase clinical efficacy and extend such therapy to other malignancies.

In a study reported in Journal of Clinical Investigation, Gros and colleagues assessed unique phenotypic traits of CD8-positive tumor-infiltrating lymphocytes and T-cell receptor β chain clonotypic frequency in 6 melanoma tumors in the attempt to identify patient-specific repertoires of the tumor-reactive CD8-positive lymphocytes. In all tumors, expression of the inhibitory receptors PD-1 (CD279), lymphocyte-activation gene 3 (LAG-3, CD223), and T-cell immunoglobulin and mucin domain 3 (TIM-3) on CD8-positive tumor-infiltrating lymphocytes identified the autologous tumor-reactive repertoire, including mutated neoantigen-specific CD8-positive lymphocytes. In contrast, only a fraction of the tumor-reactive population expressed the costimulatory receptor 4-1BB (CD137).

Deep sequencing of T-cell receptor β chain showed oligoclonal expansion of specific T-cell receptor β chain clonotypes in CD8-positive/PD-1–positive vs CD8-positive/PD-1–negative tumor-infiltrating lymphocyte populations. The T-cell receptor β chain clonotypes in the CD8-positive and the CD8-positive/PD-1–positive populations that exhibited the greatest expansion recognized autologous tumor and included clonotypes that targeted mutated antigens.

The investigators concluded, “[I]n addition to the well-documented negative regulatory role of PD-1 in T cells, our findings demonstrate that PD-1 expression on [CD8-positive] tumor-infiltrating lymphocytes] also accurately identifies the repertoire of clonally expanded tumor-reactive cells and reveal a dual importance of PD-1 expression in the tumor microenvironment.” ■

Gros A, et al: J Clin Invest 124:2246-2259, 2014.


Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.